Alpha Lipoic Acid

Alpha Lipoic Acid is a Specialty supplement available in 2 forms.

Not all forms of Alpha Lipoic Acid are equal. The form you choose determines how much Alpha Lipoic Acid actually reaches your tissues, and the difference between the best and worst forms can be substantial. R-lipoic acid is the biologically active isomer naturally produced by the body and found in mitochondria, offering superior antioxidant activity and metabolic support compared to the synthetic S-form or racemic mixtures. Research shows R-ALA is more efficiently absorbed and utilized, supporting healthy glucose metabolism, mitochondrial function, and free radical neutralization.

Alpha Lipoic Acid Preferred (Preferred Form) has a bioavailability rating of good (S2). Typical dose range: not yet documented in our database.

Alpha Lipoic Acid 100mg (Mapped Form) has a bioavailability rating of moderate (S3). Typical dose range: not yet documented in our database.

R-alpha lipoic acid is the naturally occurring, biologically active enantiomer of alpha lipoic acid. Research indicates R-ALA is absorbed more efficiently and reaches higher plasma concentrations than racemic (R,S) ALA. It functions as both a water- and fat-soluble antioxidant, supporting mitochondrial energy production, glutathione recycling, and healthy blood sugar metabolism already within normal range.

Crossover pilot study in young and elder humans comparing 500mg R-ALA vs racemic mixture: elder subjects showed greater Cmax and AUC for R-form vs racemic; younger subjects showed opposite tendency, demonstrating age-dependent enantiomer bioavailability differences PMID: 22609537

24-subject RCT crossover (12M/12F) measuring enantiomer-selective PK of racemic ALA across 4 dosage forms: R-(+)-enantiomer AUC was 64-79% of solution reference in tablet forms; solution delivers highest R-enantiomer exposure; females showed 20-26% higher enantiomeric AUC than males PMID: 25506250

Clinical study of R-ALA oral liquid formulation: accelerated absorption with high plasma concentrations achieving bioavailability approaching IV administration, markedly exceeding standard solid ALA preparations for patients requiring chronic antioxidant support PMID: 26694149

Alpha Lipoic Acid is classified as Preferred Form by FormulaForge — our top recommendation for Alpha Lipoic Acid. It carries a bioavailability rating of good (S2), meaning more of the active compound reaches your tissues per dose unit compared to lower-rated forms.

When choosing a Alpha Lipoic Acid supplement, look for the S1 (best absorption) bioavailability tier on the label. Preferred Forms have the strongest research-backed evidence for efficient absorption.

Other forms may be appropriate depending on individual goals, cost considerations, and your healthcare provider’s guidance. The best form for you depends on your specific health needs.

For Alpha Lipoic Acid, the typical dosing range is not yet documented in our database. Individual dose requirements vary based on health goals, body weight, and existing nutrient intake.

Side Effects: Specific side effect data for these forms is not yet documented in our database. In general, consult your healthcare provider regarding tolerability at higher doses.

These statements are based on structure/function research and have not been evaluated by the FDA. This information is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting or changing a supplement regimen.

The following studies and findings inform FormulaForge classifications for Alpha Lipoic Acid:

Crossover pilot study in young and elder humans comparing 500mg R-ALA vs racemic mixture: elder subjects showed greater Cmax and AUC for R-form vs racemic; younger subjects showed opposite tendency, demonstrating age-dependent enantiomer bioavailability differences PMID: 22609537

24-subject RCT crossover (12M/12F) measuring enantiomer-selective PK of racemic ALA across 4 dosage forms: R-(+)-enantiomer AUC was 64-79% of solution reference in tablet forms; solution delivers highest R-enantiomer exposure; females showed 20-26% higher enantiomeric AUC than males PMID: 25506250

Clinical study of R-ALA oral liquid formulation: accelerated absorption with high plasma concentrations achieving bioavailability approaching IV administration, markedly exceeding standard solid ALA preparations for patients requiring chronic antioxidant support PMID: 26694149